Celldex Therapeutics Inc. (CLDX) Stake Held by State Board of Administration of Florida Retirement System
State Board of Administration of Florida Retirement System continued to hold its position in shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,043 shares of the biopharmaceutical company’s stock at the end of the second quarter. State Board of Administration of Florida Retirement System owned about 0.07% of Celldex Therapeutics worth $321,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Canada Pension Plan Investment Board boosted its position in Celldex Therapeutics by 304.5% in the first quarter. Canada Pension Plan Investment Board now owns 44,900 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 33,800 shares during the last quarter. Bank of Montreal Can bought a new position in Celldex Therapeutics during the second quarter worth $188,000. Metropolitan Life Insurance Co. NY boosted its position in Celldex Therapeutics by 2.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 70,903 shares of the biopharmaceutical company’s stock worth $268,000 after buying an additional 1,412 shares during the last quarter. Emerald Acquisition Ltd. bought a new position in Celldex Therapeutics during the second quarter worth $473,000. Finally, Marcus Capital LLC boosted its position in Celldex Therapeutics by 58.5% in the second quarter. Marcus Capital LLC now owns 111,600 shares of the biopharmaceutical company’s stock worth $490,000 after buying an additional 41,200 shares during the last quarter. 78.41% of the stock is currently owned by institutional investors and hedge funds.
Celldex Therapeutics Inc. (NASDAQ:CLDX) traded down 0.26% during mid-day trading on Thursday, reaching $3.77. The company’s stock had a trading volume of 746,223 shares. Celldex Therapeutics Inc. has a 12-month low of $2.96 and a 12-month high of $18.62. The company’s market cap is $379.05 million. The firm’s 50 day moving average is $3.76 and its 200-day moving average is $4.17.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.02. Celldex Therapeutics had a negative return on equity of 47.59% and a negative net margin of 2,383.60%. The business had revenue of $1.39 million for the quarter, compared to analyst estimates of $0.96 million. During the same period in the prior year, the company earned ($0.33) earnings per share. The company’s revenue was down 36.4% on a year-over-year basis. Equities analysts anticipate that Celldex Therapeutics Inc. will post ($1.34) earnings per share for the current fiscal year.
Several analysts recently issued reports on the company. Cantor Fitzgerald reissued a “buy” rating and set a $9.00 target price on shares of Celldex Therapeutics in a research note on Monday. Brean Capital assumed coverage on Celldex Therapeutics in a research note on Tuesday, October 4th. They set a “buy” rating and a $16.00 target price on the stock. Jefferies Group lifted their target price on Celldex Therapeutics to $5.00 and gave the company a “hold” rating in a research note on Friday, August 5th. Finally, Wedbush reissued a “neutral” rating and set a $3.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, August 9th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.75.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (rindopepimut and CDX-110) is a therapeutic vaccine in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII).
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics Inc. (NASDAQ:CLDX).
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.